InvestorsHub Logo
icon url

TheHound

02/03/17 9:30 AM

#170759 RE: romaa #170758

News -----> kevetrin trial is starting

Estimated Enrollment: 10
Anticipated Study Start Date: February 9, 2017
Estimated Study Completion Date: December 31, 2017
Estimated Primary Completion Date: December 31, 2017 (Final data collection date for primary outcome measure)

https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=3
icon url

someconcerns

02/03/17 9:37 AM

#170762 RE: romaa #170758

Romaa, Thanks for posting. Important news of a clear step forward for Kevetrin.
icon url

djs7

02/03/17 9:46 AM

#170770 RE: romaa #170758

Thanks for this early catch - open label too :)
icon url

KMBJN

02/03/17 10:25 AM

#170781 RE: romaa #170758

Wow, a quick phase 2: only 10 subjects over 6 weeks - 3 weeks treatment, and 3 of follow-up. Primarily this is a safety study, looking at safety and PK of more frequent dosing. Also will look at samples (tumor biopsy, ascites, and blood) before and after treatment to see effects of kevetrin on various biomarkers (like p53, but also they were going to look at all kinds of RNA and other things) and I wouldn't expect to see much efficacy with only 3 weeks of treatment, but perhaps, just perhaps we could see some tumor shrinkage.

Was wondering how they were saying K could possibly be in a registration study in 2018. This Phase II should be very quick (for sure at least compared to the marathon of K Phase I).